ACP
TRDA icon

Acuta Capital Partners’s Entrada Therapeutics TRDA Stock Holding History

Acuta Capital Partners’s Portfolio TRDA Stock Details TRDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-89,358
Closed -$1.13M – 29
2026
Q1 		$1.13M Buy
+89,358
New +$1.02M 0.8% 23

Other funds holding TRDA

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MC
Merck & Co Rahway, New Jersey $526M AUM 175.27% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
SG
StepStone Group La Jolla, California $2.16B AUM 20.11% 1-Year Est. Return

Acuta Capital Partners's TRDA Position: Q2 2026 in Review

Acuta Capital Partners sold out of Entrada Therapeutics (TRDA) in Q2 2026, closing a stake of 89,358 shares — an estimated $1.13M sold.

Acuta Capital Partners first reported a position in TRDA in Q1 2026 and held it in 1 quarter. The position peaked at $1.13M in Q1 2026. 129 funds tracked by Wall St. Rank hold TRDA as of Q2 2026.

  • Acuta Capital Partners reported no remaining Entrada Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Acuta Capital Partners sold 89,358 Entrada Therapeutics shares in Q2 2026, an estimated $1.13M.
  • Acuta Capital Partners first reported a position in Entrada Therapeutics in Q1 2026 and held it in 1 quarter.
  • Acuta Capital Partners's Entrada Therapeutics position peaked at $1.13M in Q1 2026.
  • 129 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q2 2026.

Based on Acuta Capital Partners's 13F filing for Q2 2026, filed 14 Aug 2026.